This is the authors' abstract. We don't add key points for this paper.
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with limited therapeutic options. Integration of molecular profiling may enable personalized treatment approaches. We evaluated the clinical utility of molecularly matched treatment (MMT) in a real-life cohort of PDAC patients. PATIENTS AND METHODS: A retrospective chart review of clinical/molecular data was carried out, including all PDAC patients with a contributive molecular profile. Survival outcomes were compared across three groups: patients with actionable molecular alterations (MAs) who received MMT (MA/MMT), patients with actionable alterations without MMT (MA/No MMT), and patients without actionable alterations (No MA/No MMT). RESULTS: Among 342 patients (median age 61 years; 48% female; 95% Eastern Cooperative Oncology Group 0-1), molecular profiling was carried out using tissue (50%), liquid biopsy (45%), or both (5%). The most common gene alterations were KRAS (84%), TP53 (72%), and CDKN2A (26%). Actionable alterations were found in 69 patients (20%), with 31 (45%) receiving MMT. Targeted therapies included notably olaparib (BRCA2), trastuzumab (HER2), and KRAS G12C inhibitors. Median overall survival (OS) from metastatic diagnosis was significantly longer in the MA/MMT group (32.9 months) compared with MA/No MMT (12.9 months) and No MA/No MMT groups (17.6 months) (P = 0.0008). From initial diagnosis, OS was 34.9, 27.1, and 21.5 months, respectively (P = 0.005). Median progression-free survival from MMT initiation was 5.5 months. The mean growth modulation index was 1.7 in the MA/MMT group versus 0.8 in the MA/No MMT group (P < 0.05). In variate analysis, MMT was correlated with improved OS [hazard ratio (HR) 0.51, P < 0.001 from metastasis; HR 0.59, P < 0.01 from diagnosis]. CONCLUSION: To conclude, molecular profiling identified actionable alterations in 20% of PDAC patients. MMT was associated with a significant survival benefit, supporting molecular profiling into routine management, especially with the perspective of KRAS inhibitors.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tarabay et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: